Pre-clinical Models in Oncology

Making the choice of apt preclinical model considering the similarity to human biology and disease genotypic and phenotypic characters that it carries, marks a considerable potential to ensure higher predictability of preclinical research. The designing and interpretation of trials on human volunteers is a major challenge in the development of novel anticancer agents. Key study design elements like schedule, doses, dose administration, escalation strategy, targeted patient population, etc. rely heavily on preclinical data. This scenario requires cautious decisions on the predictability of preclinical tumor models as well as the method of analysis and translation of the results of preclinical studies. It is surely a challenging task to model for preclinical assessment of cancer immunotherapy, the most actively developing area in oncology. The need for stimulating the response of the immune system adds to the complexity of preclinical models and the applications.

  • Prevent DNA Synthesis
  • Disrupt DNA
  • Protein Inhibitors
  • Interrupt Mitosis
  • Immune System Modifiers
  • Alteration of Protein Function
  • Angiogenesis Inhibitors
  • Differentiating Agents
  • Hormone Function Interference
  • Supporting Agents

Related Conference of Pre-clinical Models in Oncology

Pre-clinical Models in Oncology Conference Speakers